MedPath

A Prospective cross-over randomized controlled trial of protein bound uremic toxin reduction between super high-flux hemodialysis and high-efficiency online hemodiafiltratio

Phase 3
Completed
Conditions
albumin lost in dialysate fluid
Registration Number
TCTR20181019001
Lead Sponsor
ipro, Japan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
12
Inclusion Criteria

•Age between 18 to 90 year-old
•ESRD on HD at least 3 months
•HD at least 3 times per week and spKt/v > 1.2
•Residual renal function < 100 ml
•AVF or AVG that BFR more than 400 ml/min
•Appropriated dry weight by BCM
•Hemodynamic stability

Exclusion Criteria

•Uncorrected heart disease and severe infection
•Advance malignancy
•Cirrhosis Child Pugh score B to C
•Pregnancy
•Contraindication for anticoagulant
•refuse inform consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Indoxyl sulphate reduction ratio end of the study percentage
Secondary Outcome Measures
NameTimeMethod
beta2 microglobulin reduction ratio end of the study percentage
© Copyright 2025. All Rights Reserved by MedPath